Abstract
Seventeen AIDS patients were enrolled in a prospective open-label dose-finding study of octreotide (Sandostatin) therapy for refractory diarrhea. Five were nonevaluable due to progression of AIDS symptomatology, and one was excluded because of lack of confirmation of HIV infection. Five of 11 evaluable patients responded to therapy (45%); two each at 50 μg and 100 μg, and one at 250 μg thrice daily doses. A sixth patient demonstrated a moderate reduction in stool volume at 250 μg thrice daily, which, although deemed clinically relevant, did not meet the criteria for response. On discontinuation of therapy, diarrhea recurred in all patients within 1–12 days, and responded to reinitiation of octreotide in those five patients who resumed treatment. Only one of the three patients with concurrent cryptosporidial infection responded to treatment. The drug was well tolerated, with mild symptomatology in three patients. Long-term treatment at a stable dose was effective in three of five treated patients for periods for seven months in one (moderate responder) and one year in two. One patient required dose increases to control symptoms, but after one year of treatment developed severe nausea following injections, which required dose cessation. One patient had partial control of his diarrhea for only three months despite two dose increases. These data suggest that octreotide may be of useful therapeutic value in HIV-associated diarrhea and that further studies are indicated.
Similar content being viewed by others
References
Pearce RB: Intestinal protozoal infection and AIDS. Lancet 2:51, 1983
Jacobs L, Gold WM, Murray W, Roberts B, Armstrong D: Salmonella infections in patients with the acquired immunodeficiency syndrome. Ann Intern Med 102:189–193, 1985
Sohn CC, Schroff W, Kliewer E, Lebel DM, Fligiol MD: Disseminated mycobacterium avium-intracellulare infection in homosexual men with acquired immunodeficiency: A histologic and immunologic study of two cases. Am J Clin Pathol 79:247–252, 1983
Wolke A, Meyers S, Adelsberg B, Bottone R, Damsker J, Schwartz IS, Janowitz D: Mycobacterium avium-intracellulare associated colitis in a patient with the acquired immunodeficiency syndrome. J Clin Gastroenterol 6:225–229, 1984
Cohen JD, Reuhlig L, Jayich SA, Tong MG, Lechago J, Shape WJ:Cryptosporidium in acquired immunodeficiency syndrome. Dig Disorder 29:773–777, 1984
Soave R, Danner RL, Honig CL, Ma P, Hart CK, Nash T, Roberts RB: Cryptosporidiosis in homosexual men. Ann Intern Med 100:504–511, 1984
DeHovitz JA, Pape JW, Boncy M, Johnson WD: Clinical manifestations and therapy ofIsospora belli patients with the acquired immunodeficiency syndrome. N Engl J Med 315:87–90, 1986
Kotler DP, Gaetz P, Lange M, Holt PR: Enteropathy associated with the acquired immunodeficiency syndrome. Ann Intern Med 101:421, 1984
Gillin J, Shike M, Alcock N, Urmacher C, Krown S, Kurtz RC, Lightdale CJ, Winawer SJ: Malabsorption and mucosal abnormalities of the small intestine in the acquired immunodeficiency syndrome. Ann Intern Med 101:619, 1985
Bauer W, Briner U, Doepfner W, Haller P, Huguein R, Marbach P, Petcher TJ, Pless J: SMS 201-995: A very potent and selective octapeptide analogue of Somatostatin with prolonged action. Life Sci 31:1133–1140, 1982
Vinik AI, Isai ST, Moattari AR, Cheung P, Eckhauser E, Cho K: Somatostatin analogue (SMS 201-995) in the management of gastroenteropancreatic tumours and diarrhea syndrome. Am J Med 81 (supl 6B):23–40, 1986
Cook DJ, Kelton JG, Stanisz M, Collins M: Somatostatin treatment for cryptosporidial diarrhea in a patient with acquired immunodeficiency syndrome (AIDS). Ann Intern Med 108:708–709, 1988
Katz MD, Erstab BL, Rose C: Treatment of severe cryptosporidium related diarrhea with octreotide in a patient with AIDS. Drug Intell Clin Pharmacol 22:134–136, 1988
Rene E, Regnier B, Laine MJ, Bonfils S: Somatostatin and cryptosporidial diarrhea during AIDS (abstract). IV International Symposium on Gastroentestinal Hormones. Can J Physiol Pharmacol Abst. No. 252, p 70, 1986
Centers for Disease Control: Classification system for human T-lymphotropic virus type III/lymphadenopathy associated virus infection. MMWR 35:334–339, 1986
Centers for Disease Control: Revision of the CDC Surveillance case definition for AIDS. MMWR 36:155, 1987
Efendic S, Mattisson O: Effect of somatostatin on intestinal motility. Acta Radiol 19:343–352, 1978
Edwards C, Cann PA, Read NW, Holdsworth CD: Effect of two new antisecretory drugs on fluid and electrolyte transport in a patient with secretory diarrhea. Gut 27:581–586, 1986
Kraenzlin ME, Wood SM, Neufeld TE, Bloom SR: Effect of long acting somatostatin-analogue, SMS 201-995, on gut hormone secretion in normal subjects. Experientia 41:738–740, 1985
Author information
Authors and Affiliations
Additional information
This study was supported by Sandoz Canada Inc.
Rights and permissions
About this article
Cite this article
Fanning, M., Monte, M., Sutherland, L.R. et al. Pilot study of Sandostatin (octreotide) therapy of refractory HIV-associated diarrhea. Digest Dis Sci 36, 476–480 (1991). https://doi.org/10.1007/BF01298877
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01298877